Neoplasms, Prostate Clinical Trial
Official title:
Retrospective Analysis of Quality of Life After Permanent Interstitial Iodine Seed Brachytherapy for Prostate Cancer
| Verified date | December 2016 |
| Source | Kantonsspital Graubuenden |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Switzerland: Ethikkommission |
| Study type | Observational |
Retrospective study to analyze Quality of life in men after iodine seed brachytherapy for localized prostate cancer
| Status | Completed |
| Enrollment | 50 |
| Est. completion date | December 2016 |
| Est. primary completion date | December 2016 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 48 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Male > 18 years of age - iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich Exclusion Criteria: - No iodine seed brachytherapy for localized prostate cancer at the University Hospital Zurich |
Time Perspective: Retrospective
| Country | Name | City | State |
|---|---|---|---|
| Switzerland | Kantonsspital Graubuenden, Department of Radiaton Oncology | Chur |
| Lead Sponsor | Collaborator |
|---|---|
| Kantonsspital Graubuenden | University of Zurich |
Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | CTCAE v4.03ff Grade 1-4 Sexual/Reproductive Function | Scale | 5 years (2009-2014) | No |
| Secondary | CTCAE v4.03ff Grade 1-4 Gastrointestinal | Scale | 5 years (2009-2014) | No |
| Secondary | CTCAE v4.03ff Grade 1-4 Renal/Genitourinary | Scale | 5 years (2009-2014) | No |
| Secondary | International Prostate Symptom Score (IPSS) | Scale | 5 years (2009-2014) | No |
| Secondary | International Index of erectile function, five items (IIEF-5) | Scale | 5 years (2009-2014) | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00970203 -
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00558363 -
ARTS - AVODART After Radical Therapy For Prostate Cancer Study
|
Phase 2 | |
| Completed |
NCT02153918 -
Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
|
Phase 2 | |
| Completed |
NCT01371513 -
Korean Practice Patterns for Screening PCA(Prostate Cancer)
|
N/A | |
| Completed |
NCT00470834 -
Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
|
Phase 4 | |
| Completed |
NCT00056407 -
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
|
Phase 3 | |
| Completed |
NCT00148928 -
Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA
|
Phase 1 | |
| Completed |
NCT01477749 -
Sipuleucel-T Manufacturing Demonstration Study
|
Phase 2 | |
| Completed |
NCT00363311 -
Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men
|
Phase 4 | |
| Completed |
NCT01337258 -
Economic Analyses of the REDUCE Trial
|
N/A | |
| Terminated |
NCT02349139 -
Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT04249947 -
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
|
Phase 1 | |
| Completed |
NCT00883909 -
ARI103094-Follow-Up Study for REDUCE Study Subjects
|
N/A |